Ozempic in teens: Do the bone and muscle loss fears hold up?

What did @9news actually say?

The clip is brief but packs in three distinct claims: that children using semaglutide for diabetes management rose 700% over three years, that GPs are broadly worried about long-term effects, and that bone and muscle loss are specific risks. Credit where it's due, the segment is careful to say the 700% figure relates to diabetes management, not weight loss. That distinction matters, and a lot of coverage has blurred it. The sourcing, though, is thin. "The Daily Telegraph reports" is doing heavy lifting here, and the original Telegraph data methodology is not explained. We're one news outlet citing another, which is not the same as citing a clinical study or a Therapeutic Goods Administration report.

The framing of doctors "sounding the alarm" is editorially loaded. Some GPs have concerns. That's not the same as a clinical consensus or a regulatory warning.

Does the science back this up?

Partially. The bone and muscle loss concerns are real and documented, but the evidence is mostly in adults, and the picture in adolescents is genuinely less clear. That uncertainty cuts both ways: it doesn't mean the risks don't exist for kids, but it also means the alarm bell tone is running ahead of the data.

On muscle loss: semaglutide and other GLP-1 receptor agonists do cause loss of lean mass alongside fat mass. Iepsen et al. (2015, Journal of Clinical Endocrinology and Metabolism) documented this in adult populations on liraglutide. A 2023 NEJM analysis of tirzepatide (Jastreboff et al.) found roughly 10-15% of total weight lost came from lean mass, which is consistent with most caloric restriction interventions but still clinically relevant in growing bodies.

On bone density: a 2022 review by Engelbrechtsen et al. in Obesity Reviews found mixed signals, with some GLP-1 agonists showing protective effects on bone markers and others showing modest reductions in bone mineral density depending on the population studied. In adolescents specifically, where peak bone mass accrual is still happening, this is a legitimate open question, not a settled alarm.

The 700% increase figure is plausible given the broader prescribing surge, but without access to the Telegraph's underlying data source, it's unverifiable here.

What did they get wrong (or right)?

They got the core concerns directionally right. Bone and muscle loss are documented in the literature and are reasonable clinical concerns, especially in pediatric populations. GPs raising questions about long-term use in children is appropriate medicine, not panic.

What they got wrong, or at least incomplete: the segment makes no distinction between semaglutide used for Type 2 diabetes in adolescents (where it has TGA and FDA approval in certain age groups) versus off-label use for weight management in children. Those are very different clinical scenarios with different risk-benefit calculations. The FDA approved semaglutide (Ozempic) for Type 2 diabetes in adults in 2017, and the TGA followed suit. Pediatric approvals are narrower and more recent. Wegovy for weight management in adolescents 12 and over was approved by the FDA in 2023, based on data from the STEP TEENS trial (Weghuber et al., 2022, NEJM), which showed meaningful weight reduction but also the same lean mass and bone questions.

Calling it simply "Ozempic" throughout without clarifying brand, indication, or formulation is a common media shorthand that genuinely misleads audiences about what drug, for what purpose, is actually being discussed.

What should you actually know?

If your child has Type 2 diabetes and a specialist has recommended semaglutide, the risk-benefit conversation looks different than if someone is considering it for childhood obesity. These are not the same decision. The STEP TEENS trial is the most relevant pediatric weight management data we have right now, and it's promising on efficacy but limited on long-term safety follow-up beyond 68 weeks. That gap is exactly what the GPs in this story are pointing at, and they're right to point at it.

Lean mass loss during rapid weight loss is not unique to GLP-1 drugs. Any significant caloric deficit does this. The clinical question is whether the loss is proportionally greater, and whether it matters more in adolescents who are still building muscle and bone. We do not have a clean answer yet. Anyone telling you they do is oversimplifying.

Australia's prescribing rules for these drugs in children remain restrictive. If you're seeing content suggesting otherwise, be skeptical. And if a GP or specialist raises long-term concerns about a growing child on these medications, that is appropriate caution, not alarmism.